ReviewEuropean journal of pediatrics2024
Pediatric MASLD: current understanding and practical approach.
Review in European journal of pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- High-Intensity Interval Training Reduces Liver Enzyme Levels and Improves MASLD-Related Biomarkers in Overweight/Obese Girls.Nutrients · 2025Trial
- Metabolic dysfunction-associated steatotic liver disease-a review of the cardiometabolic perspectives and treatments in children.International journal of obesity (2005) · 2026Review
- Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Childhood: From Disease Heterogeneity to Personalized Care.Journal of personalized medicine · 2026Review
- Subclinical Origins of Cardiometabolic Risk in Indian Adolescents: A Cross-Sectional Study.Indian pediatrics · 2026Article
- Review
- Hepatic Steatosis and Cardiovascular Risk in Obesity: A 10-Year Follow-Up Study From Childhood Into Young Adulthood.Pediatric obesity · 2026Article
- A Simple Clinical Prediction Model for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Obesity.Indian journal of pediatrics · 2026Article
- Molecular mechanisms and pathogenesis of MASH.Nature · 2026Review
- Applying Artificial Intelligence to Childhood Obesity: T2DM and MASLD Risk Predictive Models.Diagnostics (Basel, Switzerland) · 2026Review
- MASLD: Spatial Mechanisms and New Therapeutics.Biomolecules · 2026Review
- An interpretable machine learning model based on routine clinical indicators for early identification of obesity-related non-alcoholic fatty liver disease in children: a single-center retrospective study.Translational pediatrics · 2026Article
- Article
- A Cost-Utility Analysis of Two-Stage Screening Strategies Based on Waist-to-Height Ratio for Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in China.Healthcare (Basel, Switzerland) · 2026Article
- Elevated gamma glutamyl transferase levels as screening marker of stage 3-4 hepatic fibrosis in youth-onset type 2 diabetes mellitus: a retrospective chart review.BMC endocrine disorders · 2026Article
- MASLD In Children - A Distinct Phenotype?Current obesity reports · 2026Review
- Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: Role of non-invasive diagnostics and early pharmacological intervention.World journal of hepatology · 2026Review
- Association of the total cholesterol-high-density lipoprotein-glucose index with metabolic-associated steatotic liver disease: a 5-year retrospective cohort study.Frontiers in medicine · 2026Article
- Nutrition in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Journal of nutrition and metabolism · 2026Review
- Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023.Diabetology & metabolic syndrome · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most prevalent chronic liver disease in children in industrialized countries mainly due to the rise in obesity and overweight. Besides risk of progressive liver damage, MASLD also carries an increased risk of extra-hepatic morbidity, most importantly type 2 diabetes mellitus and cardiovascular disease. Important challenges remain in the prevention, detection, and treatment of this prevalent disorder. This review outlines the epidemiology and risk factors of MASLD and provides an approach to screening, diagnosis, and treatment based on current best available evidence and expert opinion. What is known: • NAFLD/MASLD is a common disorder in children strongly related to obesity/overweight and insulin resistance. • This silent disorder is underdiagnosed due to lack of awareness and lack of simple diagnostic criteria. What is new: • New diagnostic criteria have transformed NAFLD/MASLD from a diagnosis of exclusion to a positive diagnosis with simple criteria. • Effective treatments are emerging for adults and will likely become available for children. • Identifying children with NAFLD/MASLD has become even more important due to this new treatment perspective.
Indexed as
Identifiers
39560782What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.